27 August 2021 - Whether payers put biosimilars on formulary, versus originator products, depends in large part on the respective deals they strike with manufacturers over payment. 

In some cases, biosimilars may be the better deal; in others, originator products.

A look at CVS Caremark’s formulary changes for July 2021 helps to illustrate the shifting sands of payer preferences.

Read Center for Biosimilars article